Cannabis and mental health: the short answer
Cannabis cuts both ways. THC, the main intoxicating compound, can trigger anxiety, paranoia, and short-term psychosis. CBD, the non-intoxicating compound, has thinner evidence and no regulatory approval for any psychiatric diagnosis. Evidence for harm from THC is stronger than evidence for benefit from CBD. No cannabis product substitutes for assessment and treatment of a mental health condition.
THC and psychosis risk
A 2019 case-control study in The Lancet Psychiatry pooled data from 11 sites in Europe and Brazil. People who used high-potency cannabis daily had about 3 times the odds of a psychotic disorder compared with people who never used. Odds climbed with frequency and with THC content above 10%.
cannabis and mental health disorders
Age of first use matters. NIDA reports that people who start in adolescence face a higher risk of psychosis, and that high doses of THC can produce acute paranoia and hallucinations in people with no prior diagnosis.
Cannabis and Mental Health Disorders: What Research Shows
Anxiety and depression
The link runs both directions and the data are mixed. Some people report relief. Population studies also show heavy users with higher rates of anxiety and depression than non-users. Cross-sectional data cannot separate cause from self-medication.
Mental Health Effects of Cannabis: A Comprehensive Guide
- Regular use is linked to higher rates of anxiety disorders in young adults.
- Heavy use is linked to more severe depressive symptoms in some cohorts.
- Withdrawal from heavy use can produce irritability, insomnia, and low mood for 1 to 2 weeks.
CBD: what trials actually show
The FDA approved Epidiolex, a purified cannabidiol oral solution, in 2018 for seizures tied to Dravet syndrome and Lennox-Gastaut syndrome. Tuberous sclerosis complex was added in 2020. That approval covers seizures, not mood or anxiety.
Psychiatric trials of CBD are small. One double-blind study gave 600 mg of CBD to 24 people with social anxiety disorder and reported lower anxiety scores before a public speaking test. Replications with larger samples are few.
For depression, bipolar disorder, and PTSD, controlled trials of CBD are too small or too short to support a dosing recommendation. Reviews of the literature rate the certainty of evidence as low.
Use disorder numbers
The CDC estimates that about 3 in 10 people who use marijuana have marijuana use disorder. Risk is higher for people who start before age 18.
Drug interactions
CBD inhibits the CYP3A4 and CYP2C19 enzymes. The Epidiolex label warns that CBD raises blood levels of clobazam's active metabolite and can alter levels of other drugs, including some anticonvulsants and blood thinners. Check every prescription against CBD before combining them.
Label accuracy
Hemp-derived CBD is sold as a supplement in most US states. The FDA does not review those products for dose, purity, or contamination before sale. A product label is only as good as the batch testing behind it. Look for a batch-specific certificate of analysis that lists cannabinoid content and passes for heavy metals, pesticides, and residual solvents.
Who should avoid cannabis
- People with a personal or family history of psychosis or schizophrenia.
- People under 25, and anyone under 18.
- People who are pregnant or breastfeeding.
- People taking clobazam, warfarin, or drugs with a narrow therapeutic index.
- People with a history of cannabis use disorder.
What to do next
Talk to a clinician before using cannabis or CBD for a mental health symptom. Bring the product, the dose, and the certificate of analysis. If you take a psychiatric medication, ask about interactions first. If you use cannabis daily and want to stop, ask about taper plans and withdrawal support.